SB-258719

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT 7 receptor partial inverse agonist, and was the first such ligand identified for 5-HT 7 .

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT 7 receptor partial inverse agonist, and was the first such ligand identified for 5-HT 7 . Its use in research has mainly been in demonstrating the potential use for 5-HT 7 agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT 7 agonists across several different testing models.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1337400785 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.